Senior Associate, Tech Risk & Analysis - Technology Audit
Capital One Financial
Quick summary
Market check
How this pay compares to similar roles
This role pays less than 64% of similar roles. Most pay $147,225–$212,100 — the shaded band above. At the midpoint, this role pays about $160k versus about $180k for comparable roles.
Based on 240 similar postings.
Employer
Capital One Financial is a bank holding company specializing in credit cards, auto loans, banking, and savings products, known for its data-driven approach to consumer and commercial finance. Industry: Financial Services & Banking
Capital One Financial currently has 936 open roles on FindRole.
Listed pay typically runs $197,300–$225,100 across 933 roles with salary data.
Most-posted roles
At a glance
Audit Manager - Tech Risk & Analysis joins the Audit team to provide assurance services regarding critical technology functions. The role involves executing major components of audits covering cloud-based infrastructure, emerging technologies, cybersecurity risks, and third-party management. Day-to-day responsibilities include performing risk assessments of business units, designing and executing audit procedures to verify control effectiveness, analyzing evidence, and documenting processes. The professional will also manage engagement administration, including budget tracking, while providing coaching and supervision to less experienced associates. Key technical competencies include experience with software delivery, distributed systems, cloud-native architecture, infrastructure as code, identity and access management, and data protection. Candidates should possess expertise in IT control frameworks, cloud computing platforms like AWS, GCP, or Azure, and data analysis techniques to address complex risks involving application controls and information security within the organization's technology landscape.
Skills
What you'll do
What we're looking for
More like this
Capital One Financial
Capital One Financial
Capital One Financial
Fidelity Financial Services
Neurocrine
AbbVie